Toyama Submits NDA For Favipiravir In Japan
This article was originally published in PharmAsia News
Executive Summary
FujiFilm subsidiary Toyama Chemical March 30 announced the submission of a new drug application for novel antiviral flu drug favipiravir (T-705) in Japan